STUDY PROTOCOL

Protocol for a scoping review of measurement of sleep in mild cognitive impairment and early dementia [version 1; peer review: 2 approved]

Jonathan Blackman^{1,2*}, Hamish Morrison ^{1,2*}, Sam Harding ³, Katherine Lloyd ^{1,2}, Elizabeth Coulthard^{1,2}

¹Neurology, North Bristol NHS Trust, Bristol, BS10 5NB, UK

²Bristol Medical School, University of Bristol, Bristol, BS2 8DZ, UK

³Bristol Speech and Language Therapy Research Unit, North Bristol NHS Trust, Bristol, BS10 5NB, UK

* Equal contributors

V1 First published: 14 Apr 2021, 3:13
<https://doi.org/10.12688/amrcopenres.12981.1>
 Latest published: 14 Apr 2021, 3:13
<https://doi.org/10.12688/amrcopenres.12981.1>

Abstract

Background: Sleep abnormalities are increasingly recognised to emerge early in dementia, at or before the Mild Cognitive Impairment (MCI) phase. Abnormal sleep accelerates cognitive decline and may directly contribute to pathophysiology. Its accurate measurement is therefore crucial, firstly to characterise sleep abnormalities in early disease potentially facilitating earlier identification of those at risk of dementia and secondly to test sleep intervention efficacy. However, it is our a priori hypothesis that sleep outcomes are reported heterogeneously inhibiting side-by-side comparison of study findings. As a translational step towards informing choice and decisions on optimal measures, this scoping review will describe measurement tools utilised and sleep parameters currently reported in early dementia and MCI.

Methods: This scoping review follows the Joanna Briggs Institute Manual for Evidence Synthesis for Scoping Reviews. The search strategy consists of an electronic search of the CINAHL Plus, Embase, Medline, Psycinfo and British Nursing Index databases and date limited to articles published from 2000. Search results will be merged using reference management software and duplicates removed. 10% of returned titles and abstracts will be checked by each reviewing member to ensure continuity of decision making. Full-texts will be reviewed by at least two reviewers with discrepancies resolved by whole team consensus. A PRISMA flow diagram will document the selection process. Extracted data will be analysed and reported narratively.

Discussion: This scoping review will identify which sleep parameters are reported and the means by which they are measured in people

Open Peer Review

Approval Status

	1	2
version 1 14 Apr 2021	 view	 view
1. Andrea Tales , Swansea University, Swansea, UK		
2. Mariana D'Amico , Nova Southeastern University, Tampa, USA		
Any reports and responses or comments on the article can be found at the end of the article.		

with MCI or early dementia. We intend to explore differences in reporting practice within group subsets, e.g. by dementia and study subtype.

Ethics and dissemination: Ethical approval is not required due to absence of human participants. Results will be published in a peer-reviewed journal and presented at relevant academic conferences. The search strategy will be made available publicly for transparency.

Keywords

Sleep, Dementia, Mild Cognitive Impairment, MCI

This article is included in the [Alzheimer's Research UK](#) gateway.

Corresponding author: Hamish Morrison (hamish.morrison@bristol.ac.uk)

Author roles: **Blackman J:** Conceptualization, Methodology, Project Administration, Writing – Original Draft Preparation, Writing – Review & Editing; **Morrison H:** Conceptualization, Methodology, Project Administration, Writing – Original Draft Preparation, Writing – Review & Editing; **Harding S:** Conceptualization, Methodology, Supervision, Writing – Review & Editing; **Lloyd K:** Methodology, Project Administration, Writing – Review & Editing; **Coulthard E:** Conceptualization, Methodology, Supervision, Writing – Review & Editing

Competing interests: No competing interests were disclosed.

Grant information: This work was supported by the Alzheimer's Research UK. HM has received funding from BRACE and EC has received funding from BRACE and ARUK (Bristol & Bath Network).

The funders had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript.

Copyright: © 2021 Blackman J *et al.* This is an open access article distributed under the terms of the [Creative Commons Attribution License](#), which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.

How to cite this article: Blackman J, Morrison H, Harding S *et al.* **Protocol for a scoping review of measurement of sleep in mild cognitive impairment and early dementia [version 1; peer review: 2 approved]** AMRC Open Research 2021, 3:13 <https://doi.org/10.12688/amrcopenres.12981.1>

First published: 14 Apr 2021, 3:13 <https://doi.org/10.12688/amrcopenres.12981.1>

Introduction

Sleep abnormalities and circadian rhythm disturbance are well recognised in established dementia¹⁻⁵. These include objectively measured micro and macro-architectural disturbances of sleep, alongside subjective reports of reduced quantity and quality², all of which are disproportionately represented compared with age-matched controls and correlate closely with the severity of cognitive impairment^{6,7}. Circadian rhythm disorders, contributing to sleep disturbance are also generally more marked in dementia than in healthy ageing – possibly related to volumetric alterations in the Suprachiasmatic Nucleus influencing melatonin secretion⁸.

As opposed to solely representing a marker of established disease, sleep abnormalities are increasingly recognised to occur much earlier in the natural history of dementia, during and even preceding the Mild Cognitive Impairment (MCI) stage^{9,10}. Furthermore, conditions with sleep abnormalities but normal cognition e.g. chronic insomnia, increase future risk of Alzheimer's Disease (AD) dementia^{11,12}. In Lewy body dementia, sleep disturbances also precede disease onset. Rapid eye movement-sleep behaviour disorder can present several years before disease manifestation and predict cognitive impairment¹³.

Whilst such abnormalities in sleep may reflect early symptomatic manifestation of pathology, there are also plausible mechanisms by which sleep abnormalities could precipitate or accelerate pathophysiological decline¹⁴⁻¹⁸. In AD, sleep abnormalities have been hypothesised to contribute to diminished clearance of a key pathognomonic feature - beta-amyloid^{17,18}, supported by work showing the unique role of Slow Wave Sleep (SWS) in removing intracerebral toxic breakdown products (including beta amyloid) in mice¹⁹. Supporting this, SWS disruption in both healthy adults and those with AD is associated with greater levels of beta-amyloid pathology²⁰.

The pathological changes associated with multiple subtypes of dementia predate symptomatic expression of symptoms by decades^{21,22} and as such a promising future strategy will be targeting early stages of the disease when pathology is more likely to be reversible and quality of life can be retained. Given that sleep abnormalities arise early, they may provide an ideal means to identify those at highest risk of dementia and this early identification is potentially crucial when implementing therapeutic modalities to alter the pathological disease course in the future. In addition, optimising sleep itself is hypothesised as an opportunity to delay progression of neurodegenerative disease whilst simultaneously promoting physiological processes that improve cognition (particularly long-term memory consolidation), general health and wellbeing. As a result, there is much current interest in enhancing understanding of the precise nature of sleep abnormalities in dementia, their presence prior to onset of clinical symptoms and trials of interventions to improve sleep disturbances.

However, whilst providing a rich vein of opportunity for deeper characterisation and intervention, sleep is a challenging concept to measure in dementia - both due to its complex

nature and the target population. As a multidimensional concept, sleep is measurable across levels and aspects^{23,24}. For example, levels of measurement may include self-report questionnaires, behavioural measures, e.g. actigraphy, physiological means, e.g. polysomnography, and less commonly analyses at the circuit or cellular level. For the purposes of this review these will be referred to as measurement tools. Within each level, multiple aspects may be recorded e.g. sleep duration, efficiency etc., which for the purpose of this review will be referred to as sleep parameters. Furthermore, measuring sleep in MCI and early dementia is unique as it encompasses challenges not seen in healthy populations²⁵, whilst also allowing for a wider range of techniques when compared to those in later stage disease.

It is our *a priori* hypothesis that these factors ally to potentially compromise comparison and reproducibility of work designed to facilitate detailed characterisation of sleep and also to assess the effects of interventions. A recent systematic review reporting objective sleep measurement findings in MCI was unable to render specific conclusions relating to micro-architectural sleep as no two studies were found to report the same parameters¹⁰. Similarly a systematic review exploring sleep interventions in MCI was confined to narrative review due to outcome measure heterogeneity²⁶.

There is a pressing need to develop a recommended outcome set of sleep parameters and the optimal means by which they can be measured. As a translational step towards this, a scoping review was considered the most appropriate framework in exploring current research conduct within the field. To our knowledge, to date, no reviews exist describing current practices in measuring and reporting sleep within this population in clinical settings, or in interventional and observational studies, supported by an absence of systematic reviews or scoping reviews found through preliminary searches of MEDLINE, EMBASE and PROSPERO.

The primary objective of this scoping review therefore aims to address this gap in the literature by exploring which sleep outcome variables are reported and the means by which they are measured in the current literature. Secondly it aims to describe how this differs in interventional vs. observational studies and amongst separate categories/types of MCI/early dementia.

Protocol

Review question

"How is sleep currently measured and reported in the literature from studies involving participants with Mild Cognitive Impairment (MCI) and early dementia?"

Eligibility criteria

Participants

Inclusion criteria:

1. Adults aged greater than 18 (limit set to avoid excluding studies in genetic dementias); and
2. Male or Female; and

3. a) Satisfies established diagnostic criteria for MCI or minor neurocognitive disorder e.g. Albert Criteria, Peterson Criteria, DSM V.
b) Satisfies established diagnostic criteria for dementia or major neurocognitive disorder e.g. DSM-IV, ICD-10, ICD-11, NINCDSARDA, DSM-V.
4. The majority ($\geq 50\%$) of the study group has mild/early dementia/MCI as evidenced by:
 - a) MMSE ≥ 20
 - b) CDR < 2
 - c) Equivalent measure

Concept

All included studies will meet the following two criteria:

1. Sleep measurement/assessment is a key component of interest as evidenced by one or more objective relating to sleep defined within the original aims and objectives of the study.

AND

2. Sleep outcomes/parameters e.g. total sleep time, sleep efficiency, subjective experience of sleep are reported through use of a sleep outcome measure/tools which demonstrate efficacy and have been validated.

Context. This review aims to capture studies conducted in community and health-care settings.

Types of evidence sources. This scoping review will consider published, peer-reviewed articles written in English. Specifically, those reporting both experimental and quasi-experimental study designs including randomised controlled trials, before and after studies and interrupted time-series studies. In addition, analytical observational studies including prospective and retrospective cohort studies, case-control studies and analytical cross-sectional studies as well as descriptive observational study designs including case series, individual case reports and descriptive cross-sectional studies will be considered for inclusion alongside qualitative studies. Review papers, text and opinion papers are ineligible.

This proposed scoping review will be conducted in accordance with the Joanna Briggs Institute (JBI) methodology for scoping reviews²⁷.

Search strategy

An initial search of MEDLINE and EMBASE via Ovid was undertaken to identify relevant articles utilising an initial search strategy (see [Box 1](#)). The text words contained in titles and abstracts of a selection of relevant articles will be used to inform the full search strategy. The search strategy, including all identified keywords and index terms will be adapted for each included database.

Box 1. Preliminary search strategy

1. (Sleep* or slept or insomni*).ab. or (Sleep* or slept or insomni*).ti.
2. Sleep/ or exp insomnia/
3. 1 or 2
4. (MCI or MNCD or AAMI or AACD or MCD or ARCD or NMCI or AMCI or MMCI or SMCI or MCIA or LBD or FTLT or FTD).ti,ab.
5. exp Dementia/
6. (dement* or alzhem* or lewy or frontotemporal).ti,ab.
7. ((Cognit* or Neurocognit* or Neurodegenerat*) adj3 (disorder* or impair* or declin* or dement* or deficit* or dysfunction* or disease* or impair*)).ti,ab.
8. 4 or 5 or 6 or 7
9. 3 and 8
10. exp animals/ not exp humans/
11. 9 not 10
12. 11
13. limit 12 to english language
14. (measur* or assess* or question* or evaluat* or quant* or apprais* or guage* or guaging or test* or examin* or inventor* or survey*).ti,ab.
15. 9 and 14
16. 15 not 10
17. 16
18. limit 17 to english language
19. limit 18 to articles published after 1999

Due to the substantial number of included articles anticipated, reference searching within included articles will not be performed. In order to ensure that this review reflects contemporaneous practice, the search will be limited to articles published after 1999, at which point objective measurement of sleep became more routinely available.

An electronic search of the CINAHL Plus, Embase, Medline, PsychInfo and British Nursing Index databases will be performed.

Selection of eligible studies

Following the search, all identified citations will be collated and uploaded into reference management software with duplicates removed. Titles of studies clearly unrelated to the participants and concept of the scoping review will also be removed. Two reviewers will independently review 10% of the remaining abstracts against the inclusion criteria as stated. They will meet to compare their selection of articles. If agreement is above 90% between the two reviewers for at least 10% of the papers, one reviewer will review the remaining abstracts. If agreement does not reach that level, then a further 10% will be reviewed by the two reviewers and further discussion held. This process will be repeated until there is less than 10% disagreement. Once all abstracts have been reviewed,

potentially relevant sources for full text review will then be retrieved in full and their citation details imported into JBI system for the Unified Management, Assessment and Review of Information (SUMARI)²⁸. The two reviewers will review all papers independently at full text level with regular consensus meetings. Reasons for the exclusion of sources at full text will be recorded and reported in the scoping review. Any disagreements that arise between the reviewers at each stage of the selection process will be resolved through either discussion or with an additional reviewer/s. The selection

process will be reported in full within the final scoping review and presented in a Preferred Reporting Items for Systematic Reviews and Meta-Analyses extension for scoping review (PRISMA-ScR) flow diagram²⁹.

Data extraction

Data will be extracted from papers included in the scoping review by a member of the reviewing team utilising a data extraction tool developed by the reviewers (see Table 1). The data extracted will include details of the participants, study

Table 1. Data extraction form. Adapted from²⁷.

Scoping review details			
Scoping Review Title	Measurement of Sleep in Mild Cognitive Impairment and Early Dementia: A Scoping Review		
Review Question	"How is sleep currently measured and reported in studies involving participants with Mild Cognitive Impairment (MCI) and early dementia?"		
Inclusion/exclusion criteria			
Population	1. Adults > 18 2. Male or Female 3. Satisfies diagnostic criteria for Mild Cognitive Impairment or Dementia 4. Majority of group has mild cognitive symptoms as evidenced by: a. MMSE $\geq$ 20 b. CDR < 2 c. Equivalent Measure		
Concept	1. Sleep measurement / assessment defined within aims and objectives of the study. 2. Validated sleep outcome measure / tool		
Context	Community and health-care settings		
Types of Evidence Source	1. Written in English Language 2. Peer Reviewed Published Articles 3. Interventional, observational or qualitative studies		
Details and characteristics of evidence source			
Date			
Author(s)			
Title			
Country			
Context	Community		Healthcare
Participant Number			
Participant Gender (Female)			
Participant MMSE / CDR / Other			
Participant Diagnosis (%)	Mild Cognitive Impairment		Dementia
Type of Dementia(s) (%)			
Type Of Study			
Interventional / Observational	Interventional		Observational
Details/results extracted from evidence source			
Validated Outcome Measures			
Sleep Parameters Reported			

methods, concept, context and key findings regarding outcome measures pertinent to the review question. Any modifications required during the process of data extraction will be detailed within the full scoping review. Attempts will be made to contact authors to resolve issues relating to missing, unclear or incomplete data. This review is designed to highlight sleep outcomes reported in the literature rather than evaluate study quality, as such critical appraisal and risk of bias analysis will not be undertaken.

Data analysis and presentation

Attributes of each included study will be listed (headings described in [Table 2](#)).

A balloon plot will be produced combining sleep outcome parameters on one axis with validated sleep tool on the other axis (see [Figure 1](#) for example). Two further balloon plots will be produced. Each will stratify the group

Table 2. Individual study characteristics.

Table Heading	Description
Author / Year	Author and year study published
Interventional / Observational Study	Interventional or Observational Design
Study Design	Type of Study e.g. RCT / Cohort / Case-Control
Study Population	Number of Participants
Population Diagnosis	Diagnosis of Participants e.g. MCI / Early AD
Outcome Measure(s) Reported	Sleep Parameter(s) reported
Sleep Measurement Tool(s) Utilised	Validated sleep tool(s) utilised

Figure 1. Balloon plot of frequency of reported parameters by sleep measure (example).

by participant diagnosis and also by study type. These will plot the proportion of studies reporting each sleep parameter (see [Figure 2](#)) and the proportion of studies utilising each sleep measurement tool (see [Figure 3](#)). This will be followed by a narrative summary of collected data.

	TST	WASO	SL	SE	NREM1 %	Subjective Sleep
STUDY TYPE						
Interventional Studies						
Observational Studies						
MCI / DEMENTIA AETIOLOGY						
AD						
LBD						
Vascular						
FTLD						
Mixed						
Undifferentiated						

Figure 2. Stratified balloon plot template – sleep parameters.

	PSQI	ISS	ESS	CSD	Wrist Actigraphy	PSG
STUDY TYPE						
Interventional Studies						
Observational Studies						
MCI / DEMENTIA AETIOLOGY						
AD						
LBD						
Vascular						
FTLD						
Mixed						
Undifferentiated						

Figure 3. Stratified balloon plot template – measurement tools.

The results of this review will provide an understanding as to ways and means by which sleep is measured in this specific group allowing for identification of the tools and parameters most likely to facilitate comparison across studies.

Study status

Full search is currently pending.

Dissemination

Results will be published in a peer-reviewed journal and presented at relevant academic conferences. The search strategy will be made available publicly for transparency.

Data availability

No data are associated with this article

References

1. Bliwise DL: **Sleep in Normal Aging and Dementia.** *Sleep.* 1993; **16**(1): 40–81.
[PubMed Abstract](#) | [Publisher Full Text](#)
2. Benca RM, Obermeyer WH, Thisted RA, *et al.*: **Sleep and psychiatric disorders. A meta-analysis.** *Arch Gen Psychiatry.* 1992; **49**(8): 651–68; discussion 69–70.
[PubMed Abstract](#) | [Publisher Full Text](#)
3. Bublu OM, Brannick M, Mortimer J, *et al.*: **Sleep, Cognitive impairment, and Alzheimer's disease: A Systematic Review and Meta-Analysis.** *Sleep.* 2017; **40**(1).
[PubMed Abstract](#) | [Publisher Full Text](#)
4. Grace JB, Walker MP, McKeith IG: **A comparison of sleep profiles in patients with dementia with lewy bodies and Alzheimer's disease.** *Int J Geriatr Psychiatry.* 2000; **15**(11): 1028–33.
[PubMed Abstract](#) | [Publisher Full Text](#)
5. Haba-Rubio J, Marti-Soler H, Tobback N, *et al.*: **Sleep characteristics and cognitive impairment in the general population: The HypnoLaus study.** *Neurology.* 2017; **88**(5): 463–9.
[PubMed Abstract](#) | [Publisher Full Text](#)
6. Prinz PN, Vitaliano PP, Vitiello MV, *et al.*: **Sleep, EEG and mental function changes in senile dementia of the Alzheimer's type.** *Neurobiol Aging.* 1982; **3**(4): 361–70.
[PubMed Abstract](#) | [Publisher Full Text](#)
7. Vitiello MV, Borson S: **Sleep disturbances in patients with Alzheimer's disease: epidemiology, pathophysiology and treatment.** *CNS Drugs.* 2001; **15**(10): 777–96.
[PubMed Abstract](#) | [Publisher Full Text](#)
8. Swaab DF, Fliers E, Partiman TS: **The suprachiasmatic nucleus of the human brain in relation to sex, age and senile dementia.** *Brain Res.* 1985; **342**(1): 37–44.
[PubMed Abstract](#) | [Publisher Full Text](#)
9. Westerberg CE, Mander BA, Florczak SM, *et al.*: **Concurrent impairments in sleep and memory in amnesic mild cognitive impairment.** *J Int Neuropsychol Soc.* 2012; **18**(3): 490–500.
[PubMed Abstract](#) | [Publisher Full Text](#) | [Free Full Text](#)
10. D'Rozario AL, Chapman JL, Phillips CL, *et al.*: **Objective measurement of sleep in mild cognitive impairment: A systematic review and meta-analysis.** *Sleep Med Rev.* 2020; **52**: 101308.
[PubMed Abstract](#) | [Publisher Full Text](#)
11. Osorio RS, Pirraglia E, Agüera-Ortiz LF, *et al.*: **Greater risk of Alzheimer's disease in older adults with insomnia.** *J Am Geriatr Soc.* 2011; **59**(3): 559–62.
[PubMed Abstract](#) | [Publisher Full Text](#) | [Free Full Text](#)
12. Yaffe K, Laffan AM, Harrison SL, *et al.*: **Sleep-disordered breathing, hypoxia, and risk of mild cognitive impairment and dementia in older women.** *JAMA.* 2011; **306**(6): 613–9.
[PubMed Abstract](#) | [Publisher Full Text](#) | [Free Full Text](#)
13. Ferman TJ, Boeve BF, Smith GE, *et al.*: **REM sleep behavior disorder and dementia: cognitive differences when compared with AD.** *Neurology.* 1999; **52**(5): 951–7.
[PubMed Abstract](#) | [Publisher Full Text](#)
14. Ju YES, McLeland JS, Toedebusch CD, *et al.*: **Sleep quality and preclinical Alzheimer disease.** *JAMA Neurol.* 2013; **70**(5): 587–93.
[PubMed Abstract](#) | [Publisher Full Text](#) | [Free Full Text](#)
15. Roh JH, Huang Y, Bero AW, *et al.*: **Disruption of the sleep-wake cycle and diurnal fluctuation of β -amyloid in mice with Alzheimer's disease pathology.** *Sci Transl Med.* 2012; **4**(150): 150ra122.
[PubMed Abstract](#) | [Publisher Full Text](#) | [Free Full Text](#)
16. Guarnieri B, Sorbi S: **Sleep and Cognitive Decline: A Strong Bidirectional Relationship. It Is Time for Specific Recommendations on Routine Assessment and the Management of Sleep Disorders in Patients with Mild Cognitive Impairment and Dementia.** *Eur Neurol.* 2015; **74**(1–2): 43–8.
[PubMed Abstract](#) | [Publisher Full Text](#)
17. Mander BA, Winer JR, Jagust WJ, *et al.*: **Sleep: A Novel Mechanistic Pathway, Biomarker, and Treatment Target in the Pathology of Alzheimer's Disease?** *Trends Neurosci.* 2016; **39**(8): 552–66.
[PubMed Abstract](#) | [Publisher Full Text](#) | [Free Full Text](#)
18. Cedernaes J, Osorio RS, Varga AW, *et al.*: **Candidate mechanisms underlying the association between sleep-wake disruptions and Alzheimer's disease.** *Sleep Med Rev.* 2017; **31**: 102–11.
[PubMed Abstract](#) | [Publisher Full Text](#) | [Free Full Text](#)
19. Xie L, Kang H, Xu Q, *et al.*: **Sleep drives metabolite clearance from the adult brain.** *Science.* 2013; **342**(6156): 373–7.
[PubMed Abstract](#) | [Publisher Full Text](#) | [Free Full Text](#)
20. Varga AW, Wohlleber ME, Giménez S, *et al.*: **Reduced Slow-Wave Sleep Is Associated with High Cerebrospinal Fluid A β 42 Levels in Cognitively Normal Elderly.** *Sleep.* 2016; **39**(11): 2041–8.
[PubMed Abstract](#) | [Publisher Full Text](#) | [Free Full Text](#)
21. Jack CR Jr, Knopman DS, Jagust WJ, *et al.*: **Hypothetical model of dynamic biomarkers of the Alzheimer's pathological cascade.** *Lancet Neurol.* 2010; **9**(1): 119–28.
[PubMed Abstract](#) | [Publisher Full Text](#) | [Free Full Text](#)
22. Bateman RJ, Xiong C, Benzinger TLS, *et al.*: **Clinical and biomarker changes in dominantly inherited Alzheimer's disease.** *N Engl J Med.* 2012; **367**(9): 795–804.
[PubMed Abstract](#) | [Publisher Full Text](#) | [Free Full Text](#)
23. Buysse DJ: **Sleep health: can we define it? Does it matter?** *Sleep.* 2014; **37**(1): 9–17.
[PubMed Abstract](#) | [Publisher Full Text](#) | [Free Full Text](#)
24. Hall MH: **Behavioral medicine and sleep: Concepts, measures, and methods.** In: Steptoe A, ed. *Handbook of behavioral medicine: methods and applications.* Springer; 2010; 749–65.
[Publisher Full Text](#)
25. Camargos EF, Louzada FM, Nóbrega OT: **Wrist actigraphy for measuring sleep in intervention studies with Alzheimer's disease patients: application, usefulness, and challenges.** *Sleep Med Rev.* 2013; **17**(6): 475–88.
[PubMed Abstract](#) | [Publisher Full Text](#)
26. Blackman J, Swirski M, Clynes J, *et al.*: **Pharmacological and non-pharmacological interventions to enhance sleep in mild cognitive impairment and mild Alzheimer's disease: A systematic review.** *J Sleep Res.* 2020; e13229.
[PubMed Abstract](#) | [Publisher Full Text](#)
27. Peters MDJ, Godfrey C, McInerney P, *et al.*: **Chapter 11: Scoping Reviews.** (2020 version). In: Aromataris E, Munn Z, eds. *JBIManual for Evidence Synthesis.* JBI; 2020.
[Publisher Full Text](#)
28. Munn Z, Aromataris E, Tufanaru C, *et al.*: **The development of software to support multiple systematic review types: the Joanna Briggs Institute System for the Unified Management, Assessment and Review of Information (JBI SUMARI).** *Int J Evid Based Healthc.* 2019; **17**(1): 36–43.
[PubMed Abstract](#) | [Publisher Full Text](#)
29. Tricco AC, Lillie E, Zarin W, *et al.*: **PRISMA Extension for Scoping Reviews (PRISMA-ScR): Checklist and Explanation.** *Ann Intern Med.* 2018; **169**(7): 467–73.
[PubMed Abstract](#) | [Publisher Full Text](#)

Open Peer Review

Current Peer Review Status:

Version 1

Reviewer Report 17 August 2021

<https://doi.org/10.21956/amrcopenres.14054.r26761>

© 2021 D'Amico M. This is an open access peer review report distributed under the terms of the [Creative Commons Attribution License](#), which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.

Mariana D'Amico

Occupational Therapy, Tampa Bay Regional Campus, Nova Southeastern University, Tampa, FL, USA

This protocol for conducting a scoping review about sleep measurements used for individuals with mild cognitive impairment and early dementia is well written and thought out in terms of methods and parameters. Sleep is an essential health factor and identification of accurate measure is increasingly important. Completion of this protocol will add to the body of knowledge related to gaps in assessment and provide directions for future research.

Is the rationale for, and objectives of, the study clearly described?

Yes

Is the study design appropriate for the research question?

Yes

Are sufficient details of the methods provided to allow replication by others?

Yes

Are the datasets clearly presented in a useable and accessible format?

Yes

Competing Interests: No competing interests were disclosed.

Reviewer Expertise: mental health, elderly, children and youth, occupational engagement and assessments

I confirm that I have read this submission and believe that I have an appropriate level of expertise to confirm that it is of an acceptable scientific standard.

Reviewer Report 11 May 2021

<https://doi.org/10.21956/amrcopenres.14054.r26669>

© 2021 Tales A. This is an open access peer review report distributed under the terms of the [Creative Commons Attribution License](#), which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.

Andrea Tales

Centre for Innovative Ageing, Swansea University, Swansea, UK

The article very clearly describes the protocol to determine the variety of sleep parameters currently reported and how they are measured in individuals living with mild cognitive impairment and the earlier stages of dementia.

In my opinion the study design is appropriate for the research question. A potential area for further discussion is the rationale/decision to include the 'majority' of the study group with mild/early dementia /MCIwhy only the majority (i.e, equal or greater than 50%) rather than the whole of the study group having mild/early dementia/MCI?

What about potential bias in lack of publication of non-significant research findings?

Is the rationale for, and objectives of, the study clearly described?

Yes

Is the study design appropriate for the research question?

Yes

Are sufficient details of the methods provided to allow replication by others?

Yes

Are the datasets clearly presented in a useable and accessible format?

Yes

Competing Interests: No competing interests were disclosed.

Reviewer Expertise: Ageing and dementia research: EEG, psychophysics, neurocognition, vision & attention

I confirm that I have read this submission and believe that I have an appropriate level of expertise to confirm that it is of an acceptable scientific standard.